What is Intellia Therapeutics Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Intellia Therapeutics's annualizedGross Profit for the quarter that ended in Mar. 2024 was $115.74 Mil.
Intellia Therapeutics's average Total Assets over the quarter that ended in Mar. 2024 was $1,280.28 Mil. Therefore, Intellia Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 9.04%.
Intellia Therapeutics Gross-Profit-to-Asset % Historical Data
The historical data trend for Intellia Therapeutics's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Intellia Therapeutics's Gross-Profit-to-Asset %
For the Biotechnology subindustry, Intellia Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Intellia Therapeutics Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Intellia Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Intellia Therapeutics (LTS:0JBU) Business Description
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0JBU has been successfully added to your 